Tavexia Lifecare acquires 60% stake in Meyonex Pharma for ₹67.19 Crore

Listed Co AcquisitionStrategic Transactions View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.0%Reaction day

₹1.18

prior close

₹1.18

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.2%-0.2% vs market

Retailing peers, median of 56sector · industry level-0.0%+0.0% vs sector

On the reaction day the stock moved 0.2 pts less than Nifty Microcap 250 and in line with its Retailing peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.7

10m

+1.7

15m

+1.7

30m

+1.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.0+0.2-0.2-0.0+0.0

Next day

-0.8+0.9-1.7+0.3-1.1

-1.7-0.8-0.9-0.3-1.4

-0.8-0.1-0.8-0.4-0.4

+0.0-1.7+1.7-1.7+1.7

-1.7-4.3+2.6-3.4+1.7

-0.8-7.5+6.6-6.7+5.8

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Retailing peers, median of 56Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Tavexia Lifecare (formerly Sattva Sukun) will acquire a 60% controlling stake in Meyonex Pharmaceuticals for ₹67.19 Crore via cash subscription of about 2.10 crore fresh equity shares at ₹32 each. Meyonex runs a manufacturing and commercial facility in MIDC Tarapur, Maharashtra. The company is also expanding into APIs, formulations, CDMO/CRAMS, nutraceuticals, and biotech, and has amended its main object clause. Management plans further fund-raising through equity or convertible instruments.

Likely market impact

Strategic pivot into pharma manufacturing could boost long-term growth, but expect share dilution from upcoming fund-raising. Watch for execution risk.